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Abstract
Background—Pancreatic ductal adenocarcinoma represents 90% of pancreatic cancers and is an
important cause of cancer death in the United States. Operative resection remains as the only
treatment providing prolonged survival, but even after a curative resection, 5-year survival rates
are low. Our aim was to identify the prognostic factors for long-term survival after resection of
pancreatic ductal adenocarcinoma related to patients, treatments, and tumor biology.
Methods—Retrospective review identified 959 patients who underwent resection of their
pancreatic adenocarcinoma between February 1985 and December 2010, of whom 499 were
resected before November 2006 and represent the cohort we describe in this study. Patient, tumor,
and treatment-related variables were assessed for their associations with 5- and 10-year overall
survival.
Results—Of the 499 patients, 49% were female and median age was 65 years. The majority of
patients had stage IIb disease (60%). Actual 5-year survival after resection of pancreatic
adenocarcinoma was 19% (95/499), and actual 10-year survival was 10% (33/329). Significant
clinicopathologic factors predicting 5- and 10-year survival were negative margins and negative
nodal status. Interestingly, 41% (39/95) of long-term survivors had positive nodes and 24%
(23/95) had positive margins.
Conclusion—Pancreatic ductal adenocarcinoma demonstrates a very heterogeneous biology, but
patients with negative resection margins and node negative cancers are more likely to survive 5
years after resection. However, our series demonstrates that the biology of the cancer rather than
simple pathologic factors determine a patient’s prognosis.
Recently, the American Cancer Society reported that during the last decade overall rates of
cancer and cancer death have dropped.1 This is believed to be largely because of a decrease
in cigarette smoking and an increase in cancer screening. Conversely, pancreatic cancer
rates are on the rise.2 This fact, in combination with the dismal prognosis and lack of early
detection, make pancreatic cancer a growing concern. Additionally, societal awareness of
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tpancreas cancer has been heightened owing to numerous celebrities who have recently died
of the disease.
The American Cancer Society estimates that there will be 44,030 new cases of pancreatic
cancer diagnosed in 2011. This is an increase of almost 19% from 2007.2 The American
Cancer Society also estimates that there will be 37,660 deaths from pancreatic cancer in
2011, making it the fourth leading cause of cancer-related death among men and the third
leading cause of cancer-related death among women in the United States.3 An estimated
$1.9 billion is spent on the disease each year.3 Despite progress in our understanding of
pancreatic cancer, the 5-year survival for all-comers remains 5% and has not changed over
the past 3 decades.4 Even after operative resection, actual 5-year survival is only 12% in
other series.5
The aims of this study were to evaluate the actual 5- and 10-year overall survivals of
patients who have undergone operative resection of pancreatic ductal adenocarcinoma. The
second aim was to evaluate clinicopathologic factors predicting long-term survival.
METHODS
We retrospectively reviewed a database of all patients who underwent pancreatic resection
at the Massachusetts General Hospital between February 1985 and November 2006 and
identified 499 patients who underwent resection for pathologically confirmed pancreatic
ductal adenocarcinoma.
Patient-, tumor-, and treatment-related variables were evaluated. Patient factors evaluated
included age, gender, smoking status, and family history. Treatment factors included the
type of operation, adjuvant therapy, and status at last follow-up. Pathologic factors included
tumor size, nodes, metastases, TNM stage, margin (positive or negative), and vascular,
lymphatic, and perineural invasion and differentiation (well, moderate, or poor). Maximal
tumor size was determined and defined as the maximum diameter at pathological analysis.
Follow-up was obtained through office records and the social security death index.
Patients were divided into short-term survivors (3–≤20 months), intermediate term survivors
(>20–<60 months), and long-term survivors (>60 months). There were 17 perioperative
mortalities within 90 days of operative resection that were not included in Table I. Utilizing
SAS Version 9.2 (SAS, Inc, Chicago, IL), both univariate and multivariate modeling were
performed. Continuous variables were expressed as median or mean values ± standard
deviation and were compared using an independent samples t-test. Chi-square P-values were
calculated for the comparison of clinical characteristics between survivorship groupings
(Table I). Cox regression modeling was used to determine the effect of prognostic factors on
overall survival. We calculated odds ratios using logistic regression modeling to determine
factors associated with short- and long-term (Tables II and III) survivorship. Both univariate
and multivariate models were created. Kaplan–Meier methodology was used for the overall
survival curve and it was computed from the time of operative resection to the date of last
follow-up. The institutional internal review board approved this study, and none of the
authors have any conflict of interest.
RESULTS
Clinicopathologic factors
Between February 1985 and November 2006, 499 patients underwent complete gross
resection of a pathologically confirmed pancreatic ductal adenocarcinoma. The cohort was
approximately half female (49%) with a median age at diagnosis of 65 years (range, 31–91).
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tThe majority of patients (84%) underwent pancreaticoduodenectomy and had stage IIb
disease (60%). One third of the patients 35% (174/499) received chemotherapy and 66%
(329/499) received radiotherapy with chemotherapy. Even though receiving chemotherapy
is a time-dependent covariate, not receiving chemotherapy was independently associated
with decreased survival after the pancreatic operation (P = .04). The clinicopathologic
characteristics of the overall cohort are listed in Table I.
Overall survival
Patients were divided into short-term survivors (3–≤20 months), intermediate term survivors
(>20–<60 months), and long-term survivors (>60 months). The final cohort contained 499
patients, including 243 short-term survivors, 144 intermediate term survivors, and 95 long-
term survivors. The median follow-up for the entire cohort was 19 months (range, 1–271).
The overall postoperative mortality at 90 days was 3.4% (17/499). The postoperative
mortality after pan-creaticoduodenectomy was 16/418 (3.8%) and after distal
pancreatectomy 1/66 (1.5%). The 14 perioperative mortalities were included in the short-
term survivor group. Overall survival for the entire cohort is demonstrated in the Figure. The
actual 5-year survival was 19% (95/499). Almost 1/3 of patients survived between 20 and 60
months and 49% survived less than 20 months. Within the group of 95 patients who
survived 5 years, 41% had stage IIB, 31% stage IIA, 15% stage IB, and 14% stage IA
cancers. Unfortunately, 5-year survival does not represent cure, with 13% (12/95) of the
patients dying of disease after this time. Currently, 62 patients have survived between 5 and
10 years of whom 56 are still alive. The longest survivor is alive 22.5 years after her
operation. Actual 10-year survival was 10% (33/329).
Prognostic factors
Short-term, intermediate, and long-term survivors had significant differences in their R0/R1
status, histologic tumor grade, lymph node status, and TNM staging on univariate analysis
(Table I). Patients with negative margins, well-differentiated tumors, negative nodes and a
lower TNM stage were more likely to experience long-term survival. When comparing
patients who survived 5–10 years with those who survived ≥10 years, the only significant
difference was the percentage of R0 resections (P = .01). Otherwise, the differences in
clinical characteristics between the 2 survivorship groups were not statistically significant
(Table IV).
Univariate logistic regression models built to predict overall survival from the date of
resection demonstrated that positive margins, higher stage, positive nodes, and increased
tumor size were independently associated with decreased overall survival (Table II).
Multivariate analysis demonstrates that negative margins and negative nodes were
independently associated with longer survival (Table III).
DISCUSSION
Most pancreatic cancers are diagnosed at an advance stage. This, together with the
aggressiveness of the disease and the lack of effective systemic therapies, results in low rates
of overall survival. Operative resection remains the only chance for long-term survival,
despite advances in adjuvant and neoadjuvant therapies. The perioperative morbidity and
mortality of pancreatic surgery has decreased to 24% and 2%, respectively, over the last 30
years.6–8 Despite all of these improvements, the overall survival of patients with pancreatic
adenocarcinoma remains low. In our cohort of 499 patients resected between 1985 and 2006,
the actual 5- and 10-year overall survivals were 19% and 10%, respectively. The actual 5-
year overall survival of 19% is 2% higher than what we reported in 1992.9 Although these
results are better, survival remains low. Series from John Hopkins University and Memorial
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tSloan Kettering Cancer Center report a similar 5-year overall survival of 18% and 12%,
respectively (Table V).
Analysis of clinicopathologic variables in our 5-year survivors demonstrates the challenges
in prognosis for an individual patient with this disease. Increased tumor size, R1 status,
positive nodes, advanced stage disease, and not receiving chemotherapy were independently
associated with decreased survival after resection on univariate analysis. Only N stage and
margin status were significant predictors of long-term survival in our cohort. Similarly,
other large series identified margin status as a predictor of long-term survival.5,7,10
Unfortunately, margin status is often affected by the location and size of the tumor.
However, positive margins do not preclude long-term survival, because 25% of the 5-year
survivors in our series had an operation with positive margins. Negative nodes also emerged
as a prognostic factor for long-term survival in our series. Multiple studies identify stage as
a prognostic marker. We did not identify stage, but clearly nodal status and American Joint
Committee on Cancer stage are closely linked. In our cohort 41% (39/95) of 5-year
survivors and 44% (14/33) of 10-year survivors had positive lymph nodes at the time of
operative resection. These node-positive, long-term survivors exemplify the heterogeneous
tumor biology of pancreatic cancer.
The use of adjuvant chemotherapy has increased during the last 2 decades in the United
States.11 Although the aim of our study was not to measure the benefit conferred by
adjuvant therapy, we did notice that between the first 10 years of our study (1985–1995)
only 1.4% of the patients received chemotherapy, compared to 47.7% between 1995 and
2006. Some of the long-term survivors may have benefited from adjuvant therapy because
chemotherapy improved survival in our series and has been demonstrated to improve
disease-free survival after operative resection by about 10% in a randomized, controlled
trial.12 Despite a shift in adjuvant chemotherapy from 5-fluorouracil to gemcitabine over the
last 2 decades, these 2 agents have demonstrated equivalent efficacy on disease-free and
overall survivals.13,14 Therefore, the increased use of chemotherapy over time in our series
most likely improved the time to recurrence rather than the specific agent used.
Overall survival did not change significantly during the 2-decade study period; however,
perioperative 90-day mortality decreased by half from 5% to 2.5% between the first and
second decade. Perioperative mortality has been reported at most centers around υ %.8,15 We
report in this study a 3.2% perioperative 90-day mortality rate for the entire cohort. This
decrease in mortality is multi-factorial, to which the development of tertiary care centers
with multidisciplinary teams and the specialization of surgeons in pancreas surgery has
contributed.16,17
Long-term survivors present a unique cohort of patients to study. Despite positive margins
and/or positive nodes some patients are still alive. Whereas 66% of the short-term survivors
and 63% of the intermediate survivors had stage IIB disease, 41% of the 5-year survivors
had positive nodes. Conversely, 28% (17/61) of patients with stage I disease died of the
disease within 20 months, and only 44% (27/61) lived beyond 5 years. Therefore, stage
alone is unable to reliably predict prognosis. Positive margins were demonstrated in 47% of
short-term survivors and 31% of intermediate survivors, yet 24% of 5-year survivors also
underwent an R1 resection. Although these differences are significant they highlight that the
pace of progression is heterogeneous and determined by biology rather than pathology.
These tumors may have a lower number of cancer-initiating cells (aldehyde dehydrogenase-
high), cells that possess properties of self-renewal, tumor initiation, and differentiation.18
Other series have demonstrated a worse prognosis in patients who have more mesenchymal
tumors, which express vimentin, fibronectin, and N-cadherin,18–20 so perhaps these long-
term survivors may have tumors with more epithelial features. Although many gene
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tamplifications and deletions, epigenetic changes, and proteomic abnormalities have been
identified, the biology of pancreatic cancer is currently still poorly understood.
Interestingly, 5-year survival is not consistent with cure as an additional 23 patients died 5
years after their operation. Of these patients 12 died of disease, 10 patients died of unknown
causes, and 1 patient died of a non–cancer-related cause. Therefore, of our 5-year survivors,
58% (55/95) are still alive. Several patients in our cohort have relapsed >10 years after the
resection of their primary pancreatic adenocarcinoma. Two patients developed isolated lung
metastases and underwent pulmonary resections to help control their disease. This late
relapse perhaps suggests that the interaction of the immune system with the tumor varies
over time and during the progression of the malignancy. The cells we later identify as
recurrences may have been controlled by the immune system from the time of the resection
of the primary cancer. This phenomenon of tumor escape can occur through a variety of
mechanisms, including inhibition or suppression of T-cell recognition, an increase in
regulatory T cells, alterations in the immunologic checkpoints resulting in downregulation
of T cells, and many others.21–23 By studying this cohort of patients, we hope to elucidate
some of the contributing factors to recurrence.
In conclusion, this series confirms that ductal adenocarcinoma of the pancreas has an
implacable prognosis, even after resection, with actual 5- and 10-year survivals of 19% and
10%, respectively. However, our series exemplifies that a patient’s prognosis is determined
by tumor biology rather than clinicopathologic factors, because there is a striking
discordance between pathology, stage, and survival. Additional efforts are needed to
decrease morbidity associated with pancreatic resection and improve screening for early
detection; however, mostly we need to intensify the search for new and effective therapies
by understanding the diverse biology of the long-term survivors.
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Overall survival for all patients (Kaplan–Meier).
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Table II
Univariate logistic regression model predicting long-term survival
Long-term univariate Odds ratio (95% confidence interval) P-value
Head 0.712 (0.40–1.28) .258
Male 1.232 (0.78–1.94) .368
Pancreaticoduodenectomy 0.911 (0.50–1.67) .763
R0R1:R1 0.447 (0.27–0.75) .002
Age/10 1.009 (0.81–1.26) .936
Received chemo 1.499 (0.94–2.39) .089
H vs D:H 0.851 (0.46–1.59) .612
pN 0.318 (0.20–0.51) <.001
Poorly differentiated 1.142 (0.72–1.81) .572
Tumor size 0.774 (0.64–0.94) .010
Stage 3–4* NA —
T stage 3–4 0.434 (0.26–0.72) .001
*
Because there were no stage 3–4 patients in the long-term survivor group, this effect was not analyzable (NA).
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Table III
Multivariate logistic regression model predicting long-term survival
Multivariate
Odds ratio (95%
confidence interval) P-value
R0/R1:R1 0.472 (0.27–0.82) .008
pN 0.300 (0.18–0.50) <.001
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Table IV
Patients characteristics of long-term survivors by length of survival time
Variable
Long-term survivors
(overall), n (%) (n = 95)
≥5- and <10-year
survivorship, n (%) (n = 62)
≥10-yr survivorship,
n (%) (n = 33)
Chi-square
P-value
Gender NS
  Female 42 (45) 30 (48) 12 (37)
  Male 53 (55) 32 (52) 21 (63)
Tumor location NS
  Head 77 (81) 51 (82) 26 (79)
  Body 7 (7) 5 (8) 2 (6)
  Tail 8 (9) 4 (7) 4 (12)
Operation NS
  Pancreaticoduodenectomy 79 (83) 53 (86) 26 (79)
  Distal pancreatectomy 11 (12) 7 (11) 4 (12)
  Total pancreatectomy 5 (5) 2 (3) 3 (9)
Stage of resected patients NS
  IA 13 (14) 9 (15) 4 (12)
  IB 14 (15) 7 (11) 7 (21)
  IIA 29 (31) 22 (35) 7 (21)
  IIB 39 (41) 24 (39) 15 (46)
pT NS
  1 13 (14) 9 (15) 5 (13)
  2 18 (19) 8 (13) 10 (31)
  3 64 (67) 45 (72) 18 (56)
pN NS
  0 56 (59) 38 (61) 19 (56)
  1 39 (41) 24 (39) 14 (44)
Margin (R0R1) .014
  Negative 72 (76) 42 (68) 30 (91)
  Positive 23 (24) 20 (32) 3 (9)
Perineural invasion NS
  No 23 (25) 14 (22) 9 (29)
  Yes 56 (60) 42 (68) 14 (45)
  Unknown 16 (15) 6 (10) 9 (26)
Perivascular invasion NS
  No 32 (34) 18 (29) 13 (42)
  Yes 22 (23) 17 (28) 4 (13)
  Unknown 41 (43) 27 (43) 15 (45)
Grade NS
  Moderately differentiated 40 (42) 25 (40) 15 (46)
  Poorly differentiated 39 (37) 25 (40) 14 (42)
  Well differentiated 10 (10) 9 (14) 2 (6)
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